Business Summary
Mesoblast Limited specializes in developing allogeneic, “off‑the‑shelf” cellular medicines designed to treat severe inflammatory conditions. The company’s late‑stage pipeline is anchored in proprietary mesenchymal lineage cell therapy platforms. Its leading candidates are Ryoncil (remestemcel‑L), a bone marrow‑derived MSC therapy, and Revascor (rexlemestrocel‑L), a second‑generation precursor cell therapy currently in advanced trials for chronic heart failure and chronic low back pain. Both therapies have already reached commercialization in Japan and Europe through licensing partnerships.
Company Overview. . .
Gain full access to all our premium investment intelligence
Plans from $9.99 per week, cancel anytime.
Subscribe or upgrade to Full Stock Picks to view this content
Already a member? Sign in
Gain full access to all our premium investment intelligence
Plans from $9.99 per week, cancel anytime.
Subscribe or upgrade to Full Stock Picks to view this content
Already a member? Sign in